Microbot Medical filings document formal disclosures tied to the LIBERTY Endovascular Robotic System and the company’s commercial-stage medical-device operations. Recent Form 8-K reports furnish Regulation FD press releases on U.S. market release activity, healthcare-system adoption, procedure use, medical-society occupational-protection guidelines, and publication of the ACCESS-PVI pivotal study.
The filings also record Item 8.01 other-event disclosures and capital-markets matters, including an at-the-market common stock program under a shelf registration statement. These records describe the company’s Nasdaq-listed common stock, product commercialization, clinical-evidence communications, commercial organization updates, and related exhibit filings.
Microbot Medical Inc. (MBOT) filed a preliminary S-3 prospectus registering up to 14,688,572 shares of common stock for resale by selling stockholders. The shares may be issued upon exercise of outstanding preferred investment options, including 13,989,115 Series J options at an exercise price of $4.50 per share. This prospectus does not cover the issuance of the underlying shares to the holders and the company is not selling any shares.
Microbot will not receive proceeds from stockholder resales. If all 14,688,572 options are exercised for cash, the company may receive up to approximately $64.8 million in gross proceeds; certain options permit cashless exercise. Shares outstanding were 67,158,044 as of October 10, 2025. Listed methods permit brokerage transactions, block trades, privately negotiated sales, and short sales after the registration statement is declared effective.
MBOT trades on Nasdaq; the last reported closing price on October 10, 2025 was $2.92.
Microbot Medical Inc. (MBOT) filed a preliminary S-3 registering up to 900,153 shares of common stock for resale by selling stockholders. The shares may be issued upon exercise of outstanding preferred investment options held by those stockholders. The company is not selling shares in this offering and will not receive proceeds from any resales.
Microbot may receive up to approximately $2.1 million in gross proceeds only if all registered options are exercised for cash; some options allow cashless exercise. The plan of distribution permits multiple methods, including short sales after the registration statement is declared effective. Examples include Noam Rubenstein 283,548 and Michael Vasinkevich 577,223 from the selling stockholder table. Shares outstanding were 67,158,044 as of October 10, 2025. MBOT last closed at $2.92 on October 10, 2025.
Microbot Medical Inc. reports that on October 6, 2025, a holder exercised 1,324,488 existing series H preferred investment options for 1,324,488 shares of common stock at an exercise price of $2.10 per share. Under a previously disclosed inducement letter agreement, the holder also received 1,324,488 new series J preferred investment options.
This transaction represents the third and final closing under that inducement arrangement, which was required to occur on or before October 15, 2025. Microbot also issued 66,224 preferred investment options to H.C. Wainwright & Co., LLC under a May 29, 2024 engagement letter, as amended.
The new preferred investment options and the Wainwright preferred investment options, and the shares underlying them, were issued as unregistered securities in reliance on Section 4(a)(2) of the Securities Act and may be resold only pursuant to registration or an applicable exemption. Shares issuable upon exercise of the existing options are already registered under a post-effective amendment to a Form S-1 registration statement. The company also noted it issued a press release on October 7, 2025 announcing this third closing.
Microbot Medical Inc. reported several recent equity transactions involving preferred investment options and common stock. On September 29, 2025, a holder exercised 600,000 series H preferred investment options for 600,000 shares of common stock at an exercise price of $2.10 per share and, under a prior inducement letter, received 600,000 new series J preferred investment options. The company also issued 30,000 preferred investment options to H.C. Wainwright & Co., LLC under an existing engagement letter, all in unregistered transactions relying on Section 4(a)(2) of the Securities Act.
Separately, on September 23, 2025, Microbot issued 374,167 shares of common stock upon exercise of an equal number of preferred investment options at exercise prices between $1.875 and $2.6625, generating approximately $896,000 in gross proceeds before fees. The resale of shares issuable from the previously issued series H options is covered by an effective registration statement, while the new options and their underlying shares remain unregistered and subject to resale restrictions.
Microbot Medical Inc. reported that the Japanese Patent Office has granted the company its first patent in Japan covering the core LIBERTY® System technology.
The patent relates to a compact robotic device used to drive and control the movement of at least one long surgical tool, supporting the company’s robotic surgery platform. The company also furnished a press release with the same information as an exhibit to the report.
Microbot Medical Inc. filed a Form D reporting a completed Regulation D private offering under Rule 506(b). The issuer raised aggregate proceeds of $25,244,903, of which $25,244,903 has been sold and $0 remains. The filing states the total offering amount reflects the aggregate exercise price of inducement preferred investment options and placement-agent preferred investment options. The placement agent received cash fees totaling $2,095,542 and was also granted 1,342,694 preferred investment options exercisable for common stock at prices ranging from $1.875 to $2.6625. The offering was a new notice with a first sale date of 2025-09-16, claimed a minimum investment of $0, and was not part of a business combination. The Form D was signed by CFO Rachel Vaknin on 2025-09-29.
Microbot Medical Inc. filed a current report to share that its Chief Executive Officer, Harel Gadot, will appear on Benzinga All Access at 10:45 a.m. ET on Wednesday, September 24, 2025. During the interview, he is expected to discuss the recent FDA clearance of the Company’s LIBERTY® system and how the Company has planned for its commercialization in the United States.
The Company furnished a related press release as Exhibit 99.1, and this communication is being treated as “furnished” rather than “filed” under securities laws. The filing highlights ongoing communication with the market about Microbot Medical’s efforts to redefine the peripheral endovascular space with its LIBERTY® technology.
Microbot Medical Inc. disclosed that its board’s Compensation Committee approved special one-time cash bonuses for several executives and non‑management directors. CEO, President and Chairman Harel Gadot received $158,115, CTO Simon Sharon received approximately $64,200, and executive officer Rachel Vaknin received approximately $32,500. The committee also authorized one-time cash payments of $30,000 to $45,000 for each non‑management board member.
The committee noted that these payments reflect, in part, that the executives had previously waived 30–50% of their prorated 2023 base salaries under the company’s May 2023 cost restructuring plan.
Microbot Medical Inc. entered into an inducement agreement with certain holders of its existing preferred investment options, who agreed to exercise options to buy up to 13,989,115 shares of common stock for cash in exchange for new Series J preferred investment options to buy up to 13,989,115 shares at an exercise price of $4.50 per share. At a first closing, holders exercised options for up to 12,064,627 shares, generating approximately $25.2 million in gross proceeds, and a second closing is expected to add exercises for up to 1,924,488 shares for approximately $4.0 million in gross proceeds.
The company plans to use the net proceeds to advance development, commercialization and regulatory activities for its LIBERTY® Robotic System, pursue potential acquisitions, expand applications from its IP portfolio, and for working capital and general corporate purposes. Microbot also issued unregistered new options to investors and to H.C. Wainwright & Co., which served as exclusive placement agent and will receive cash fees, expense reimbursements, and additional preferred investment options tied to current and future cash exercises.
Microbot Medical Inc. furnished an update under Regulation FD by making new investor presentation materials available on its website. The slides can be accessed through the ‘Investors’ section under ‘IR Resources’ and then ‘Additional Resources.’
The company also highlighted its participation in the H.C. Wainwright Annual Investor Conference in New York, where President, CEO and Chairman Harel Gadot is scheduled to present on September 9, 2025, with a live webcast available through the ‘Events’ section of the website. The presentation materials are furnished as Exhibit 99.1 to this report and are expressly described as furnished, not filed, which limits their treatment under certain securities law liability provisions.